ELVN Enliven Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1672619 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.7%
TTM EPS YoY6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-16.8%
ROA-16.4%
ROIC (approx.)-19.4%
Asset turnover—
Leverage & solvency
Liabilities / assets2.3%
Debt / equity0.00x
Current ratio45.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.58x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $28.02M | $29.00M | $20.69M | $21.25M | $18.23M | $21.49M | $24.89M | $20.72M |
| SG&A expense | $8.02M | $8.21M | $7.14M | $13.04M | $6.87M | $7.09M | $6.80M | $6.17M |
| Operating income | -$36.05M | -$37.21M | -$27.82M | -$34.28M | -$25.10M | -$28.58M | -$31.69M | -$26.90M |
| Income tax | — | — | — | $0 | $0 | $0 | — | $0 |
| Net income | -$27.70M | -$32.48M | -$23.63M | -$29.67M | -$20.15M | -$25.34M | -$28.54M | -$23.18M |
| EBITDA | -$36.03M | -$37.20M | -$27.81M | -$34.20M | -$25.03M | -$28.50M | -$31.62M | -$26.83M |
| EPS (basic) | -0.36 | -0.49 | -0.38 | — | -0.32 | -0.49 | -0.57 | — |
| EPS (diluted) | -0.36 | -0.49 | -0.38 | — | -0.32 | -0.49 | -0.57 | — |
| Weighted avg. shares (diluted) | 77.98M | 66.17M | 62.80M | — | 62.09M | 52.11M | 50.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $151.67M | $135.50M | $132.18M | $98.90M | $101.73M | $119.44M | $101.70M | $124.17M |
| Short-term investments | $732.68M | $759.65M | $320.22M | $363.73M | $375.83M | $371.07M | $187.85M | $189.32M |
| Current assets | $894.76M | $907.34M | $463.14M | $474.88M | $482.68M | $495.62M | $294.32M | $318.13M |
| PP&E, net | $201,000 | $140,000 | $20,000 | $34,000 | $399,000 | $462,000 | $404,000 | $458,000 |
| Total assets | $897.23M | $910.22M | $464.85M | $476.17M | $490.88M | $503.89M | $302.57M | $325.76M |
| Current liabilities | $19.47M | $14.16M | $11.49M | $16.57M | $14.65M | $15.21M | $13.97M | $15.91M |
| Total liabilities | $20.28M | $15.07M | $11.49M | $16.57M | $14.75M | $15.41M | $14.27M | $15.91M |
| Shareholders' equity | $876.95M | $895.15M | $453.37M | $459.60M | $476.12M | $488.47M | $288.30M | $309.85M |
| Shares outstanding | 73.56M | 73.25M | 60.89M | 59.44M | 59.26M | 59.23M | 49.04M | 48.94M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.55M | -$18.53M | -$19.29M | -$15.84M | -$13.28M | -$17.06M | -$24.13M | -$17.20M |
| Capital expenditure | $94,000 | $99,000 | $0 | $0 | -$1,000 | $139,000 | $20,000 | $0 |
| Free cash flow | -$12.65M | -$18.63M | -$19.29M | -$15.84M | -$13.28M | -$17.20M | -$24.15M | -$17.20M |
| Investing cash flow | $26.33M | -$441.57M | $42.53M | $12.38M | -$4.06M | -$183.59M | $1.43M | $727,000 |
| Financing cash flow | $2.39M | $463.42M | $10.05M | $623,000 | -$368,000 | $218.38M | $234,000 | $39.97M |
| Depreciation & amortization | $13,000 | $7,000 | $14,000 | $83,000 | $62,000 | $81,000 | $74,000 | $63,000 |
| Stock-based compensation | $8.06M | $13.91M | $7.40M | $12.31M | $7.18M | $7.72M | $6.80M | $5.34M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.